Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

Fineline Cube Dec 18, 2024

The China’s Center for Drug Evaluation (CDE) website has signaled that GlaxoSmithKline’s (GSK; NYSE: GSK)...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management

Fineline Cube Dec 18, 2024

Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...

Company Deals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Fineline Cube Dec 18, 2024

In a significant development in the alternative asset management sector, companies such as Blackstone and...

Company Drug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA

Fineline Cube Dec 17, 2024

China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...

Drug

AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Policy / Regulatory

NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has issued the...

Hospital

Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License

Fineline Cube Dec 17, 2024

Singapore-based Perennial Real Estate Holdings Limited has announced that its Perennial General Hospital in Tianjin...

Company Drug

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks

Fineline Cube Dec 17, 2024

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed its decision to...

Company Deals

Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline

Fineline Cube Dec 17, 2024

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has...

Company Medical Device

MicroPort CardioFlow’s VitaFlow Liberty Receives Marketing Approval in Turkey

Fineline Cube Dec 17, 2024

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced that its second-generation transcatheter aortic...

Company Drug

Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD

Fineline Cube Dec 17, 2024

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced significant progress for...

Company

Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility

Fineline Cube Dec 17, 2024

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is making a significant investment in its...

Company Drug

Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis

Fineline Cube Dec 17, 2024

US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...

Company Drug

J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment

Fineline Cube Dec 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...

Company Drug

Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment

Fineline Cube Dec 17, 2024

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...

Company Drug

Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation

Fineline Cube Dec 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for Irpagratinib Regulatory Study

Fineline Cube Dec 17, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents

Fineline Cube Dec 17, 2024

GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...

Company Drug

GSK’s Jemperli Receives Positive CHMP Opinion for Endometrial Cancer Indication Extension

Fineline Cube Dec 17, 2024

The UK-based pharmaceutical giant GSK (NYSE: GSK) has received a positive opinion from the European...

Company Drug

GSK’s Jemperli Receives FDA Breakthrough Therapy Designation for Rectal Cancer Treatment

Fineline Cube Dec 17, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that it has received Breakthrough Therapy Designation...

Posts pagination

1 … 190 191 192 … 612

Recent updates

  • Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials
  • GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection
  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.